MARKET

PIRS

PIRS

Pieris Pharmaceu
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.700
+0.040
+2.41%
After Hours: 1.700 0 0.00% 16:00 05/25 EDT
OPEN
1.650
PREV CLOSE
1.660
HIGH
1.705
LOW
1.645
VOLUME
226.18K
TURNOVER
0
52 WEEK HIGH
6.15
52 WEEK LOW
1.610
MARKET CAP
125.97M
P/E (TTM)
-2.4429
1D
5D
1M
3M
1Y
5Y
Pieris Pharmaceuticals (PIRS) Loses 41.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Pieris Pharmaceuticals (PIRS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a pot...
Zacks · 05/18 13:35
Pieris Pharmaceuticals To Present at H.C. Wainwright Global Investment Conference
BOSTON, MA / ACCESSWIRE / May 18, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other in...
ACCESSWIRE · 05/18 12:00
After Plunging 45.5% in 4 Weeks, Here's Why the Trend Might Reverse for Pieris Pharmaceuticals (PIRS)
The heavy selling pressure might have exhausted for Pieris Pharmaceuticals (PIRS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indic...
Zacks · 05/16 13:35
How Many Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) Shares Do Institutions Own?
If you want to know who really controls Pieris Pharmaceuticals, Inc. ( NASDAQ:PIRS ), then you'll have to look at the...
Simply Wall St. · 05/16 12:29
The Daily Biotech Pulse: Veru Shares Up On COVID Candidate Update, FDA Approves Lilly's COVID Treatment, Latest On Sanofi-AstraZeneca RSV Vaccine
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/11 13:37
Pieris Pharmaceuticals (PIRS) Reports Q1 Loss, Lags Revenue Estimates
Pieris Pharmaceuticals (PIRS) delivered earnings and revenue surprises of 41.67% and 2.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/11 12:45
BRIEF-Pieris Pharmaceuticals Inc - Net Loss Was $5.1 Million Or $0.07 Per Share For The Quarter Ended March 31, 2022
reuters.com · 05/11 11:48
Recap: Pieris Pharmaceuticals Q1 Earnings
  Pieris Pharmaceuticals (NASDAQ:PIRS) reported its Q1 earnings results on Wednesday, May 11, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Benzinga · 05/11 11:45
More
No Data
Learn about the latest financial forecast of PIRS. Analyze the recent business situations of Pieris Pharmaceu through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

100.00%Strong Buy
0.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average PIRS stock price target is 8.00 with a high estimate of 8.00 and a low estimate of 8.00.
High8.00
Average8.00
Low8.00
Current 1.700
EPS
Actual
Estimate
-0.24-0.18-0.12-0.06
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 130
Institutional Holdings: 41.44M
% Owned: 55.92%
Shares Outstanding: 74.10M
TypeInstitutionsShares
Increased
21
4.52M
New
20
5.26M
Decreased
22
2.18M
Sold Out
14
2.74M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.55%
Pharmaceuticals & Medical Research
+0.01%
Key Executives
Non-Executive Chairman/Independent Director
James Geraghty
President/Chief Executive Officer/Director
Stephen Yoder
Chief Financial Officer/Senior Vice President
Thomas Bures
Senior Vice President/Chief Scientific Officer
Hitto Kaufmann
Senior Vice President/General Counsel/Secretary
Ahmed Mousa
Senior Vice President
Tim Demuth
Senior Vice President
Shane Olwill
Independent Director
Ann Barbier
Independent Director
Peter Kiener
Independent Director
Christopher Kiritsy
Independent Director
Michael Richman
Independent Director
Maya Said
Independent Director
Matthew Sherman
No Data
No Data
About PIRS
Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways. The Company’s lead respiratory Anticalin-based drug candidate, PRS-060/AZD1402, which is antagonizes IL-4R alpha, thereby inhibiting by IL-4 and IL-13, two cytokines, small proteins mediating signaling between cells within the human body, known to be mediators in the inflammatory cascade that drive the pathogenesis of asthma and other inflammatory diseases. The lead IO Anticalin-based drug candidate in its pipeline, cinrebafusp alfa, which is designed to target the immune receptor 4-1BB and the tumor target HER2. Cinrebafusp alfa is a genetic fusion of a variant of an HER2-targeting antibody with an Anticalin protein specific for 4-1BB.

Webull offers kinds of Pieris Pharmaceuticals Inc stock information, including NASDAQ:PIRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PIRS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PIRS stock methods without spending real money on the virtual paper trading platform.